[1] CHEN WQ, ZHENG RS, BAADE PD, et al.Cancer statistics in China, 2015[J]. CA Cancer J Clin, 2016, 66(2): 115-132.
[2] ZHOU MG, WANG HD, ZENG XY, et al.Mortality, morbidity, and risk factors in China and its provinces, 1990-2017: a systematic analysis for the Global Burden of Disease Study 2017[J]. Lancet, 2019, 394(10204): 1145-1158.
[3] RAVAIOLI M, ODALDI F, CUCCHETTI A, et al.Long term results of down-staging and liver transplantation for patients with hepatocellular carcinoma beyond the conventional criteria[J]. Sci Rep, 2019, 9(1): 3781.
[4] AFFONSO BB, GALASTRI FL, DA MOTTA LEAL FILHO JM, et al. Long-term outcomes of hepatocellular carcinoma that underwent chemoembolization for bridging or downstaging[J]. World J Gastroenterol, 2019, 25(37): 5687-5701.
[5] MEHTA N, GUY J, FRENETTE CT, et al.Excellent Outcomes of Liver Transplantation Following Down-Staging of Hepatocellular Carcinoma to Within Milan Criteria: A Multicenter Study[J]. Clin Gastroenterol Hepatol, 2018, 16(6): 955-964.
[6] CLAVIENPA, LESURTEL M, BOSSUYT PMM, et al.Recommendations for liver transplantation for hepatocellular carcinoma: an international consensus conference report[J]. Lancet Oncol, 2012, 13(1): e11-22.
[7] 中国医师协会器官移植医师分会, 中华医学会器官移植学分会. 中国肝癌肝移植临床实践指南(2018版)[J]. 中华消化外科杂志, 2019, 18(1): 1-7.
[8] MEHTA N, YAO FY.Living donor liver transplantation for hepatocellular carcinoma: To expand (beyond Milan) or downstage (to Milan)?[J]. Liver Transpl, 2018, 24(3): 327-329.
[9] LLOVET JM, PAVEL M, RIMOLA J, et al.Pilot study of living donor liver transplantation for patients with hepatocellular carcinoma exceeding Milan Criteria (Barcelona Clinic Liver Cancer extended criteria)[J]. Liver Transpl, 2018, 24(3): 369-379.
[10] KIM YJ, JUNGJ, JOO JH, et al.Combined transarterial chemoembolization and radiotherapy as a first-line treatment for hepatocellular carcinoma with macroscopic vascular invasion: Necessity to subclassify Barcelona Clinic Liver Cancer stage C[J]. Radiother Oncol, 2019, 141: 95-100.
[11] YOON SM, RYOO BY, LEE SJ, et al.Efficacy and Safety of Transarterial Chemoembolization Plus External Beam Radiotherapy vs Sorafenib in Hepatocellular Carcinoma With Macroscopic Vascular Invasion: A Randomized Clinical Trial[J]. JAMA Oncol, 2018, 4(5): 661-669.
[12] YOON SM, LIM YS, WON HJ, et al.Radiotherapy plus transarterial chemoembolization for hepatocellular carcinoma invading the portal vein: long-term patient outcomes[J]. Int J Radiat Oncol Biol Phys, 2012, 82(5): 2004-2011.
[13] 中华人民共和国国家卫生健康委员会医政医管局. 原发性肝癌诊疗规范(2019年版)[J]. 中国实用外科杂志, 2020, 40(2): 121-138.
[14] WEI XB, JIANG YB, ZHANG XP, et al.Neoadjuvant Three-Dimensional Conformal Radiotherapy for Resectable Hepatocellular Carcinoma With Portal Vein Tumor Thrombus: A Randomized, Open-Label, Multicenter Controlled Study[J]. J Clin Oncol, 2019, 37(24): 2141-2151.
[15] CHOI JY, YU JI, PARK HC, et al.The possibility of radiotherapy as downstaging to living donor liver transplantation for hepatocellular carcinoma with portal vein tumor thrombus[J]. Liver Transpl, 2017, 23(4): 545-551. |
